Eco Survey: Pharma focus turns to value, innovation over volumes
Well, look who decided to grow up! India's pharma sector, long the world's reliable workhorse for sheer volume, seems to have traded its bulk generic swagger for a sophisticated, high-value strut. It’s less about flooding the market with aspirin and more about precision-engineered biosimilars – essentially, trading the 'quantity over quality' mantra for a 'quality *is* the quantity' ethos. Forget the corner shop, we’re talking bespoke pharmaceutical tailoring now, and honestly, it’s about time this sleeping giant started flexing its intellectual muscles beyond just sheer production capacity.
Indeed, this strategic pivot is driven by a clear understanding of global market demands. India's pharmaceutical sector is increasingly moving towards high-value products such as complex generics and biosimilars, signaling a mature evolution in its capabilities. Concurrently, the medical devices industry is also experiencing robust growth, with exports reaching new heights, showcasing a broader expansion in healthcare manufacturing. Key to sustaining and accelerating this expansion are advanced manufacturing technologies, which are enabling more precise, efficient, and innovative production processes, solidifying India's position as a major global pharmaceutical and healthcare manufacturing hub.
